According to the latest research report by IMARC Group, The global viral vector manufacturing market size reached US$ 1,200.1 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 7,681.6 Million by 2032, exhibiting a growth rate (CAGR) of 22.4% during 2024-2032. More Info:- https://www.imarcgroup.com/viral-vector-manufacturing-market

1. Global Viral Vector
Manufacturing Market
Research and Forecast
Report 2024-2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved

2. About IMARC Group
International Market Analysis Research and Consulting Group is a leading adviser on management
strategy and market research worldwide. We partner with clients in all regions and industry
verticals to identify their highest-value opportunities, address their most critical challenges, and
transform their businesses.
IMARC’s information products include major market, scientific, economic and technological
developments for business leaders in pharmaceutical, industrial, and high technology
organizations. Market forecasts and industry analysis for biotechnology, advanced materials,
chemicals, food and beverage, travel and tourism, nanotechnology and novel processing methods
are at the top of the company’s expertise.
IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and
markets with close cooperation at all levels of the client organization. This ensures that our clients
achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting
results.

3. Report Highlight
and Description
According to the latest report by IMARC Group, titled "Viral Vector
Manufacturing Market: Global Industry Trends, Share, Size, Growth,
Opportunity and Forecast 2024-2032," the global viral vector manufacturing
market size reached US$ 1,200.1 Million in 2023.
A viral vector is a tool used to deliver genetic material into cells. This process
is performed inside a living organism (in vivo) or in cell culture (in vitro). It is
widely used in gene and cell therapy to replace defective genes with functional
genes.
Besides this, viral vectors are also utilized to treat different diseases, such as
heart defects, metabolic diseases, neurodegenerative disorders, and oncolytic
therapies, to target and kill tumor cells. In recent years, there has been a
significant rise in viral vector manufacturing due to the rising prevalence of
genetic disorders.
Request for a PDF sample of this report: https://www.imarcgroup.com/viral-
vector-manufacturing-market/requestsample

4. Report Description
Global Viral Vector Manufacturing Market Trends:
The market is primarily driven by the rising number of cancer patients across the globe as viral vectors are used
in suicide gene therapy, oncolytic virotherapy, anti-angiogenesis, and therapeutic gene vaccines to treat a wide
range of cancers. In addition, the increasing number of clinical studies undertaken on viral vectors is contributing
to the market growth. Besides this, as viral vectors are efficient carriers of virus-disabling sequences, they are
widely used to deliver HIV-inhibiting transgenes to human hematopoietic stem cells (HSCs).
This, coupled with the rising utilization of viral vectors in novel drug delivery, is positively influencing the market
growth. Furthermore, the introduction of advanced therapies, the rising number of gene therapy-based research
and development (R&D) activities, and the increasing manufacturing capacities of key players are anticipated to
propel the market growth.
Looking forward, IMARC Group expects the market value to reach US$ 7,681.6 Million by 2032, exhibiting a
CAGR of 22.4% during 2024-2032.
View Report TOC, Figures and Tables: https://www.imarcgroup.com/viral-vector-manufacturing-market

5. Report
Segmentation
Breakup by Type:
• Adenoviral Vectors
• Adeno-associated Viral Vectors
• Lentiviral Vectors
• Retroviral Vectors
• Others
Breakup by Disease:
• Cancer
• Genetic Disorders
• Infectious Diseases
• Others
Breakup by Application:
• Gene Therapy

6. Report
Segmentation
• Vaccinology
Breakup by End User:
• Pharmaceutical and Biopharmaceutical Companies
• Research Institutes
Breakup by Region:
• North America
• Asia-Pacific
• Europe
• Latin America
• Middle East and Africa

7. Competitive
Landscape with
Key Players
• Cognate BioServices Inc. (Charles River
Laboratories International Inc.)
• F. Hoffmann-La Roche AG
• FinVector Oy
• FUJIFILM Holdings Corporation
• Kaneka Eurogentec S.A. (Kaneka Corporation)
• Lonza Group AG
• Merck KGaA
• Oxford Biomedica plc
• REGENXBIO Inc.
• Sanofi S.A.
• Thermo Fisher Scientific Inc.
• uniQure N.V.

8. Key Questions
Answered in
the Report
What was the size of the global viral vector manufacturing market
in 2023?
What is the expected growth rate of the global viral vector
manufacturing market during 2024-2032?
What has been the impact of COVID-19 on the global viral vector
manufacturing market?
What are the key factors driving the global viral vector
manufacturing market?
What is the breakup of the global viral vector manufacturing market
based on the type?
What is the breakup of the global viral vector manufacturing market
based on the disease?
What is the breakup of the global viral vector manufacturing market
based on the application?
What are the key regions in the global viral vector manufacturing
market?
Who are the key players/companies in the global viral vector
manufacturing market?

9. Table of
Contents
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Viral Vector Manufacturing Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Type
6.1 Adenoviral Vectors
6.1.1 Mark et Trends
6.1.2 Mark et Forecast
6.2 Adeno-associated Viral Vectors
6.2.1 Mark et Trends
6.2.2 Mark et Forecast
6.3 Lentiviral Vectors
6.3.1 Mark et Trends
6.3.2 Mark et Forecast

10. Table of
Contents
6.4 Retroviral Vectors
6.4.1 Mark et Trends
6.4.2 Mark et Forecast
6.5 Others
6.5.1 Mark et Trends
6.5.2 Mark et Forecast
7 Market Breakup by Disease
7.1 Cancer
7.1.1 Market Trends
7.1.2 Mark et Forecast
7.2 Genetic Disorders
7.2.1 Mark et Trends
7.2.2 Mark et Forecast
7.3 Infectious Diseases
7.3.1 Mark et Trends
7.3.2 Mark et Forecast
7.4 Others
7.4.1 Mark et Trends
7.4.2 Mark et Forecast
8 Market Breakup by Application
8.1 Gene Therapy
8.1.1 Mark et Trends
8.1.2 Mark et Forecast
8.2 Vaccinology
8.2.1 Mark et Trends
8.2.2 Mark et Forecast
9 Market Breakup by End User
9.1 Pharmaceutical and Biopharmaceutical Companies
9.1.1 Mark et Trends
9.1.2 Mark et Forecast
For more information, visit :
https://www.imarcgroup.com/viral -vector-manufacturing -
market/toc

11. Disclaimer
© 2023 IMARC All Rights Reserved
This Publication and all it’s contents unless otherwise mentioned are copyrighted in the
name of International Market Analysis Research and Consulting (IMARC). No part of this
publication may be reproduced, repackaged, redistributed or resold in whole or in any part.
The publication may also not be used in any form or by and means graphic electronic or
mechanical, including photocopying, recording, taping or by information storage or retrieval,
or by any other form, without the express consent of International Market Analysis Research
and Consulting (IMARC).
Disclaimer: All contents and data of this publication, including forecasts, data analysis and
opinion have been based on information and sources believed to be accurate and reliable at
the time of publishing. International Market Analysis Research and Consulting makes no
representation of warranty of any kind as to the accuracy or completeness of any Information
provided. IMARC accepts no liability whatsoever for any loss or damage resulting from
opinion, errors or inaccuracies if any found this publication.
IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of
International Market Analysis Research and Consulting. All other trademarks used in this
publication are registered trademarks of their respective companies.

12. Contact Us
Visit us at :
https://www.imarcgroup.com
TELEPHONE: +1-631-791-1145
E-MAIL: sales@imarcgroup.com